World Health Organization Issues Alert Over Acute Shortage of Weight-Loss Medications
Fewer than one in 10 patients who could benefit from weight-loss injections like Wegovy have access to them, states the global health agency as it publishes its inaugural recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for increased and just access to GLP-1 medication.
Per projections, over two billion will be living with obesity by 2030 if no action is taken.
"Our new guidance affirms that obesity is a long-term condition that can be addressed with thorough and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key obstacles to broad access to the jabs that can assist patients in reducing substantial weight, explains the agency.
Skinny Jab Scarcity
Even in the present most optimistic outlook, the production of such drugs would only suffice for about 100 million people – under 10% of those who need them, according to the health organization.
The recommendation urges countries and companies to expand availability, via measures like voluntary licensing.
The intellectual property rights on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs replicate a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so individuals reduce food intake.
Individuals usually see weight reduction after several weeks of commencing the weekly injections.
Studies indicates people may regain a significant portion after a year of halting the treatment, because their usual hunger return.
To be overweight or obese elevates your risk for developing medical conditions, like type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity impacts individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
